tiprankstipranks
TipRanksStock Market NewsMESO NewsAnalysts’ Top Healthcare Picks: Mesoblast (MESO), Y-Mabs Therapeutics (YMAB)
Blurbs

Analysts’ Top Healthcare Picks: Mesoblast (MESO), Y-Mabs Therapeutics (YMAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mesoblast (MESOResearch Report), Y-Mabs Therapeutics (YMABResearch Report) and Stealth Biotherapeutics (MITOResearch Report) with bullish sentiments.

Mesoblast (MESO)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Mesoblast, with a price target of $16.00. The company’s shares closed last Tuesday at $3.51, close to its 52-week low of $3.23.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.7% and a 32.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Janux Therapeutics Inc.

Currently, the analyst consensus on Mesoblast is a Strong Buy with an average price target of $13.00.

See the top stocks recommended by analysts >>

Y-Mabs Therapeutics (YMAB)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Y-Mabs Therapeutics today and set a price target of $63.00. The company’s shares closed last Tuesday at $12.44.

According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of -29.6% and a 19.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Y-Mabs Therapeutics with a $45.50 average price target.

Stealth Biotherapeutics (MITO)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Stealth Biotherapeutics, with a price target of $1.50. The company’s shares closed last Tuesday at $0.27, close to its 52-week low of $0.16.

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -10.2% and a 32.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Stealth Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MESO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More